文献速递血栓与止血

皮下注射罗米司亭治疗儿童免疫性血小板减少症的单臂长期疗效与安全性研究

A single-arm, long-term efficacy and safety study of subcutaneous romiplostim in children with immune thrombocytopenia.
PubMed 文献 · Blood Adv · 2023-01-01

这项3b期单臂多中心研究纳入203例病程≥6个月、血小板≤30×10⁹/L的1至<18岁免疫性血小板减少症患儿,每周皮下注射罗米司亭(1 μg/kg滴定至10 μg/kg)以维持血小板50至200×10⁹/L。前6个月血小板反应时间中位数为50.0%,36个月治疗期间升至78.2%;治疗相关不良事件发生率27.6%,严重治疗相关不良事件3.9%。长期罗米司亭可产生持续的治疗中血小板反应,总体安全性特征与既往研究一致。

要点

  • 前6个月血小板反应时间中位数50.0%,36个月治疗期间升至78.2%。
  • 11例(5.4%)获得持续反应,即连续≥24周无需ITP药物且血小板≥50×10⁹/L。
  • 治疗相关不良事件56例(27.6%),严重治疗相关不良事件8例(3.9%)。

核心结论

  • 长期罗米司亭治疗可使患儿获得持续的治疗中血小板反应,总体安全性特征与既往研究一致。

研究设计与样本

  • 3b期、单臂、多中心研究,纳入203例年龄≥1至<18岁、ITP病程≥6个月且血小板计数≤30×10⁹/L的儿童,接受每周皮下罗米司亭(1 μg/kg滴定至10 μg/kg)治疗。
  • 主要终点为前6个月治疗期间血小板反应时间百分比(血小板≥50×10⁹/L且前4周内未使用救援药物)。
  • 部分患者接受骨髓检查。

主要发现

  • 中位年龄10.0岁,中位治疗时长约3年,中位平均每周剂量6.9 μg/kg。
  • 95例(46.8%)终止治疗,其中因疗效不足终止43例(21.2%)。
  • 前6个月血小板反应时间中位数(四分位距)为50.0%(16.7%-83.3%),36个月总体治疗期间升至78.2%(26.7%-90.4%)。
  • 11例(5.4%)获得持续反应(连续≥24周无需ITP药物且血小板≥50×10⁹/L)。
  • 治疗相关不良事件56例(27.6%),严重治疗相关不良事件8例(3.9%),均导致终止治疗,其中中和抗体4例(罗米司亭3例、TPO 1例)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Romiplostim is a thrombopoietin (TPO) receptor agonist approved for children and adults with immune thrombocytopenia (ITP) for ≥6 months, recommended as second-line treatment. This phase 3b, single-arm, multicenter study investigated long-term efficacy and safety of romiplostim in children ≥1 to <18 years old with ≥6 months' ITP duration and platelet counts ≤30 × 109/L. Children received weekly subcutaneous romiplostim (1 μg/kg titrated to 10 μg/kg) to maintain platelets within 50 to 200 × 109/L. A subset underwent bone marrow examinations. The primary end point was percentage of time with platelet response during the first 6 months' treatment (counts ≥50 × 109/L without rescue medication within the preceding 4 weeks). Overall, 203 patients (median age, 10.0 years) received ≥1 dose of romiplostim, median treatment duration was ∼3 years, and median average weekly dose was 6.9 μg/kg. Ninety-five (46.8%) discontinued (lack of efficacy, n = 43 [21.2%]). Platelet responses were achieved a median (interquartile range) of 50.0% (16.7%-83.3%) of the time during the first 6 months, increasing to 78.2% (26.7%-90.4%) during the overall 36-month treatment period. Eleven patients (5.4%) achieved sustained responses (consecutive counts ≥50 × 109/L without ITP medications for ≥24 weeks). Treatment-related adverse events (AEs) occurred in 56 patients (27.6%), with 8 (3.9%) experiencing serious treatment-related AEs; all of these led to discontinuation, including 4 cases of neutralizing antibodies (romiplostim, n = 3; TPO, n = 1). Bleeding occurred in 141 patients (69.5%), decreasing over time; grade ≥3 bleeding events occurred in 20 (9.9%). At year 2, eight of 63 evaluable patients (12.7%) had grade 2 reticulin. Long-term romiplostim resulted in sustained on-treatment platelet responses with an overall safety profile consistent with previous studies. This trial was registered at www.clinicaltrials.gov as #NCT02279173.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Grainger J, Bussel J, Tarantino M, et al. A single-arm, long-term efficacy and safety study of subcutaneous romiplostim in children with immune thrombocytopenia. Blood Adv. 2023. PMID: 35413092. doi:10.1182/bloodadvances.2021006014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。